Brand and Other Names:Forteo, parathyroid hormone
- Classes: Parathyroid Hormone Analogs
Dosing & Uses
Dosage Forms & Strengths
prefilled injectable pen
- 600mcg/mL (2.4mL)
Treatment of postmenopausal women with osteoporosis at high risk for fracture; increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture; treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture
Administer initially while patient is sitting or lying down in the event of orthostasis
20 mcg SC once daily into thigh or abdominal wall
CrCl <30 mL/min: Dose adjustment not necessary; bioavailability and half-life may increase
Orphan designation for treatment of idiopathic osteoporosis
Orphan indication sponsor
- Biomeasure, Inc; 27 Maple St; Milford, MA 01757-3650
Orphan designation for treatment of hypoparathyroidism
- Entera Bio, Ltd; Kiryat Hadassah Minrav Bldg, 5th Floor, P. O. Box 12117; Jeusalem 91220, Israel
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Hypercalcemia (transient increases 4-6 hours after dose; 11% of women, 6% of men)
Antibodies to teriparatide (3% of women in long-term treatment)
Chest pain (3%)
Leg cramps (3%)
Tooth disorder (2%)
Black Box Warnings
In rats, increased risk of osteosarcoma has been observed; do not prescribe for patients at high risk for osteosarcoma (eg, those with Paget disease, unexplained alkaline phosphatase elevation, open epiphyses, or previous external-beam or implant radiation therapy involving skeleton)
High risk for osteosarcoma
Hypercalcemia may predispose to digoxin toxicity
Orthostatic hypotension may occur
Urolithiasis, bone metastases, metabolic bone disease (other than osteoporosis), open epiphyses, Paget disease, preexisting hypercalcemia
Use of drug for >2 years during patient lifetime not recommended
Use caution in cardiovascular disease, renal and/or hepatic impairment, and patients with active or recent urolithiasis
Pregnancy & Lactation
Pregnancy category: C
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Recombinant human parathyroid hormone; stimulates osteoblast function, increases calcium absorption, and increases renal tubular reabsorption of calcium; these effects lead to increased bond mineral density, bone mass, and strength
Onset: 3 months
Peak serum time: Teriparatide, 30 min; calcium, 4-6 hr
Concentration: Calcium, 9.68 mg/dL
Vd: 0.12 L/kg
Half-life: 5 min (IV); 1 hr (SC)
Total body clearance: Women, 62 L/hr; men, 94 L/hr
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs